Star Imaging and Path Lab Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹5(3.52%)
Premium (ELP)
The Initial Public Offering of Star Imaging and Path Lab Limited's culminated in its successful listing on Aug 18, 2025 at the BSE trading platform. The company secured 48,92,000 Shares through this capital market exercise, with 39,20,000 Shares allocated to new capital formation and ₹13.80 Cr to existing shareholder liquidity.
Investors participated within the price parameters of ₹135 to ₹142, with minimum investment requirements of 1000 shares. The subscription period from Aug 08, 2025 to Aug 12, 2025 witnessed active investor engagement across categories.
Following the subscription closure, share allotment was processed on Aug 13, 2025. The subsequent listing established a public market for the company's shares, enabling price discovery and secondary market trading for investors.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Star Imaging and Path Lab Limited, founded in 2004, is a healthcare company offering a wide range of diagnostic services, including radiology tests like X-rays, CT scans, MRIs, and ultrasounds, as well as pathology services such as blood tests, microbiology, PCR, and histopathology. With advanced equipment and skilled medical professionals, the company focuses on delivering accurate and timely results to support effective diagnosis and treatment. Operating across multiple regions, it serves both individual patients and healthcare institutions. As of September 30, 2024, the company employs 209 full-time staff, including executive directors.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
- All-in-one testing facility – provides both pathology and radiology services at a single location
- Strong industry reputation – well-known with a solid track record in healthcare diagnostics
- Skilled management team – led by experienced professionals with deep sector expertise
- Legal cases in progress – ongoing matters involving the company, promoters, and directors may affect business if outcomes are negative
- Missing financial reports – past non-filing of consolidated financials with RoC could raise regulatory issues
- CSR rules not followed – failure to meet CSR duties from FY 2021–22 to FY 2023–24 may lead to penalties
- Mr. Pawan Gupta
Star Imaging and Path Lab Limited
Kfin Technologies Limited